High-resolution mass spectrometry for glycoproteomics

References

• 1. Solá RJ, Griebenow K. Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs 24(1), 9–21 (2010).
  Medline CASGoogle Scholar
• 2. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr. Opin. Biotechnol. 22(6), 868–876 (2011).
  Medline CASGoogle Scholar
• 3. Pan S, Chen R, Aebersold R, Brentnall TA. Mass spectrometry based glycoproteomics – from a proteomics perspective. Mol. Cell. Proteomics 10(1), R110.003251 (2011).
  MedlineGoogle Scholar
• 4. Bagdonaite I, Malaker SA, Polasky DA et al. Glycoproteomics. Nat. Rev. Methods Primers 2(1), 48 (2022).
  CASGoogle Scholar
• 5. Chen S-Y, Dong M, Yang G et al. Glycans, glycosite, and intact glycopeptide analysis of n-linked glycoproteins using liquid handling systems. Anal. Chem.. 92(2), 1680–1686 (2020).
  Medline CASGoogle Scholar
• 6. Zhang Y, Fonslow BR, Shan B, Baek MC, Yates JR 3rd. Protein analysis by shotgun/bottom-up proteomics. Chem. Rev. 113(4), 2343–2394 (2013).
  Medline CASGoogle Scholar
• 7. Mechref Y. Use of CID/ETD mass spectrometry to analyze glycopeptides. Curr. Protoc. Protein Sci. 68(1), 12.11.1–12.11.11 (2012).
  Google Scholar
• 8. Quaranta A, Spasova M, Passarini E et al. N-Glycosylation profiling of intact target proteins by high-resolution mass spectrometry (MS) and glycan analysis using ion mobility-MS/MS. Analyst 145(5), 1737–1748 (2020).
  Medline CASGoogle Scholar
• 9. Hackett WE, Zaia J. Calculating glycoprotein similarities from mass spectrometric data. Mol. Cell. Proteomics 20, 100028 (2021).
  Medline CASGoogle Scholar
• 10. Good DM, Wirtala M, McAlister GC, Coon JJ. Performance characteristics of electron transfer dissociation mass spectrometry. Mol. Cell. Proteomics 6(11), 1942–1951 (2007).
  Medline CASGoogle Scholar
• 11. Ren D, Pipes GD, Liu D et al. An improved trypsin digestion method minimizes digestion-induced modifications on proteins. Anal. Biochem. 392(1), 12–21 (2009).
  Medline CASGoogle Scholar
• 12. Hanisch F-G. O-Glycoproteomics: site-specific O-glycoprotein analysis by CID/ETD electrospray ionization tandem mass spectrometry and top-down glycoprotein sequencing by in-source decay MALDI mass spectrometry. Methods Mol. Biol. 842, 179–189 (2012).
  Medline CASGoogle Scholar
• 13. Wohlschlager T, Scheffler K, Forstenlehner IC et al. Native mass spectrometry combined with enzymatic dissection unravels glycoform heterogeneity of biopharmaceuticals. Nat. Commun. 9(1), 1713 (2018).
  MedlineGoogle Scholar
• 14. Toby TK, Fornelli L, Kelleher NL. Progress in top-down proteomics and the analysis of proteoforms. Annu. Rev. Anal. Chem. 9(1), 499 (2016).
  Medline CASGoogle Scholar
• 15. Zubarev RA, Makarov A. Orbitrap mass spectrometry. Anal. Chem. 85(11), 5288–5296 (2013).
  Medline CASGoogle Scholar
• 16. Shajahan A, Heiss C, Ishihara M, Azadi P. Glycomic and glycoproteomic analysis of glycoproteins-a tutorial. Anal. Bioanal. Chem. 409(19), 4483–4505 (2017).
  Medline CASGoogle Scholar
• 17. Denisov E. Damoc E Lange O Makarov A Orbitrap mass spectrometry with resolving powers above 1,000,000. International Journal of Mass Spectrometry. 325–327, 80–85 (2012).
  CASGoogle Scholar
• 18. Gutierrez-Reyes CD, Jiang P, Atashi M et al. Advances in mass spectrometry-based glycoproteomics: an update covering the period 2017–2021. Electrophoresis 43(1–2), 370–387 (2022).
  Medline CASGoogle Scholar
• 19. Ceroni A, Maass K, Geyer H et al. GlycoWorkbench: A Tool for the Computer-Assisted Annotation of Mass Spectra of Glycans. J. Proteome Res. 7(4), 1650–1659 (2008).
  Medline CASGoogle Scholar
• 20. Hanisch F-G. Top-down sequencing of O-glycoproteins by in-source decay matrix-assisted laser desorption ionization mass spectrometry for glycosylation site analysis. Anal Chem. 83(12), 4829–4837 (2011).
  Medline CASGoogle Scholar
• 21. Roberts DS, Mann M, Melby JA et al. Structural o-glycoform heterogeneity of the SARS-CoV-2 spike protein receptor-binding domain revealed by top-down mass spectrometry. J. Am. Chem. Soc. 143(31), 12014–12024 (2021).
  Medline CASGoogle Scholar
• 22. Krusemark CJ, Frey BL, Belshaw PJ, Smith LM. Modifying the charge state distribution of proteins in electrospray ionization mass spectrometry by chemical derivatization. J. Am. Soc. Mass Spectrom. 20, 1617–1625 (2009).
  Medline CASGoogle Scholar
• 23. Bern M, Kil YJ, Becker C. Byonic: Advanced Peptide and Protein Identification Software. Curr. Protoc. 1–13 (2012).
  Google Scholar
• 24. Solntsev SK, Shortreed MR Frey BL, Smith LM. Enhanced Global Post-translational Modification Discovery with MetaMorpheus. J Proteome Res 17, 1844–1851 (2018).
  Medline CASGoogle Scholar
• 25. Zeng W-F, Cao W-Q, Liu M-Q, He S-M, Yang P-Y. Precise, fast and comprehensive analysis of intact glycopeptides and modified glycans with pGlyco3. Nat. Methods 18(12), 1515–1523 (2021).
  Medline CASGoogle Scholar
• 26. Avtonomov DM, Polasky DA, Ruotolo BT, Nesvizhskii AI. IMTBX and Grppr: software for top-down proteomics utilizing ion mobility-mass spectrometry. Anal. Chem. 90(3), 2369–2375 (2018).
  Medline CASGoogle Scholar
• 27. Kawahara R, Chernykh A, Alagesan K et al. Community evaluation of glycoproteomics informatics solutions reveals high-performance search strategies for serum glycopeptide analysis. Nat. Methods 18(11), 1304–1316 (2021).
  Medline CASGoogle Scholar
• 28. Yang Y, Liu F, Franc V, Halim LA, Schellekens H, Heck A. Hybrid mass spectrometry approaches in glycoprotein analysis and their usage in scoring biosimilarity. Nat. Commun. 7, 13397 (2016).
  Medline CASGoogle Scholar
• 29. Crutchfield CA, Thomas SN, Sokoll LJ, Chan DW. Advances in mass spectrometry-based clinical biomarker discovery. Clin. Proteomics 13(1), 1 (2016).
  MedlineGoogle Scholar
• 30. Xu M, Yang A, Xia J et al. Protein glycosylation in urine as a biomarker of diseases. Transl. Res. 253, 95–107 (2022).
  MedlineGoogle Scholar
• 31. Xu M, Hu W, Liu Z et al. Glycoproteomic bioanalysis of exosomes by LC–MS for early diagnosis of pancreatic cancer. Bioanalysis 13(11), 861–864 (2021).
  CASGoogle Scholar
• 32. Zhang Y, Jiao J, Yang P, Lu H. Mass spectrometry-based n-glycoproteomics for cancer biomarker discovery. Clin. Proteomics 11(1), 1–14 (2014).
  MedlineGoogle Scholar
• 33. Alharbi RA. Proteomics approach and techniques in identification of reliable biomarkers for diseases. Saudi J. Biol. Sci. 27(3), 968–974 (2020).
  Medline CASGoogle Scholar
• 34. Gao Z, Wu Z, Han Y et al. Aberrant fucosylation of saliva glycoprotein defining lung adenocarcinomas malignancy. ACS Omega 7(21), 17894–17906 (2022).
  Medline CASGoogle Scholar
• 35. Llop E, Guerrero PE, Duran A et al. Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma. World J. Gastroenterol. 24(24), 2537 (2018).
  Medline CASGoogle Scholar
• 36. Chen I-H, Aguilar HA, Paez Paez JS et al. Analytical pipeline for discovery and verification of glycoproteins from plasma-derived extracellular vesicles as breast cancer biomarkers. Anal. Chem. 90(10), 6307–6313 (2018).
  Medline CASGoogle Scholar
• 37. Tabarés G, Radcliffe CM, Barrabés S et al. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology. 16(2), 132–145 (2006).
  Medline CASGoogle Scholar
• 38. Scott E, Munkley J. Glycans as biomarkers in prostate cancer. Int. J. Mol. Sci. 20(6), 1389 (2019).
  Medline CASGoogle Scholar